OBJECTIVES: Assess the relationship between inhaled corticosteroid use (ICS) and weight (BMI) in pediatric patients with moderate-severe asthma. Assess if the number of emergency department (ED) visits correlates with overall BMI trajectory. Assess the trend of prescribing biologic therapy in pediatric patients with moderate-severe asthma and determine its relationship with weight (BMI). METHODS: A retrospective chart review was performed on 93 pediatric patients with moderate-severe asthma to determine the relationship between ICS use and weight (BMI), biologic therapy and BMI, and number of ED visits and BMI trajectory. A mixed effects model was employed with the correlation between repeated measures accounted for through the random effects. RESULTS: There is a statistically significant increase of 0.369 kg/m2 in BMI trajectory per year in subjects on high-dose steroids compared to an increase of 0.195 kg/m2 in the low dose group (p < 0.05). The BMI of subjects initiated on biologic therapy (omalizumab or mepolizumab) had a statistically significant decrease in BMI trajectory of 0.818 kg/m2 per year (p < 0.05). Subjects with ≥5 ED visits due to asthma exacerbations had a significantly higher BMI trajectory (p < 0.05). CONCLUSIONS: The potency of ICS use in pediatric patients with moderate-severe asthma affects BMI trajectory; the higher the dose, the greater the projected BMI increase per year. Initiation of biologic therapy decreased BMI trajectory over time. Lastly, those with frequent ED visits had a higher BMI trend. Future prospective studies are warranted that further evaluate the potential metabolic impacts of ICS and assess the effects of biologic therapy on BMI.
OBJECTIVES: Assess the relationship between inhaled corticosteroid use (ICS) and weight (BMI) in pediatric patients with moderate-severe asthma. Assess if the number of emergency department (ED) visits correlates with overall BMI trajectory. Assess the trend of prescribing biologic therapy in pediatric patients with moderate-severe asthma and determine its relationship with weight (BMI). METHODS: A retrospective chart review was performed on 93 pediatric patients with moderate-severe asthma to determine the relationship between ICS use and weight (BMI), biologic therapy and BMI, and number of ED visits and BMI trajectory. A mixed effects model was employed with the correlation between repeated measures accounted for through the random effects. RESULTS: There is a statistically significant increase of 0.369 kg/m2 in BMI trajectory per year in subjects on high-dose steroids compared to an increase of 0.195 kg/m2 in the low dose group (p < 0.05). The BMI of subjects initiated on biologic therapy (omalizumab or mepolizumab) had a statistically significant decrease in BMI trajectory of 0.818 kg/m2 per year (p < 0.05). Subjects with ≥5 ED visits due to asthma exacerbations had a significantly higher BMI trajectory (p < 0.05). CONCLUSIONS: The potency of ICS use in pediatric patients with moderate-severe asthma affects BMI trajectory; the higher the dose, the greater the projected BMI increase per year. Initiation of biologic therapy decreased BMI trajectory over time. Lastly, those with frequent ED visits had a higher BMI trend. Future prospective studies are warranted that further evaluate the potential metabolic impacts of ICS and assess the effects of biologic therapy on BMI.
Authors: Danielle R Stevens; William Grobman; Rajesh Kumar; Leah M Lipsky; Stefanie N Hinkle; Zhen Chen; Andrew Williams; Matthew C H Rohn; Jenna Kanner; Seth Sherman; Pauline Mendola Journal: Am J Epidemiol Date: 2021-05-04 Impact factor: 4.897
Authors: Zuelma A Contreras; Zhanghua Chen; Theano Roumeliotaki; Isabella Annesi-Maesano; Nour Baïz; Andrea von Berg; Anna Bergström; Sarah Crozier; Liesbeth Duijts; Sandra Ekström; Esben Eller; Maria P Fantini; Henrik Fomsgaard Kjaer; Francesco Forastiere; Beatrix Gerhard; Davide Gori; Margreet W Harskamp-van Ginkel; Joachim Heinrich; Carmen Iñiguez; Hazel Inskip; Thomas Keil; Manolis Kogevinas; Susanne Lau; Irina Lehmann; Dieter Maier; Evelien R van Meel; Monique Mommers; Mario Murcia; Daniela Porta; Henriëtte A Smit; Marie Standl; Nikos Stratakis; Jordi Sunyer; Carel Thijs; Maties Torrent; Tanja G M Vrijkotte; Alet H Wijga; Kiros Berhane; Frank Gilliland; Leda Chatzi Journal: Eur Respir J Date: 2018-09-27 Impact factor: 16.671
Authors: Nikos Stratakis; Erika Garcia; Aruna Chandran; Tingju Hsu; Akram Alshawabkeh; Izzuddin M Aris; Judy L Aschner; Carrie Breton; Allison Burbank; Carlos A Camargo; Kecia N Carroll; Zhanghua Chen; Erika C Claud; Dana Dabelea; Anne L Dunlop; Amy J Elliott; Assiamira Ferrara; Jody M Ganiban; James E Gern; Diane R Gold; William A Gower; Irva Hertz-Picciotto; Margaret R Karagas; Catherine J Karr; Barry Lester; Leslie D Leve; Augusto A Litonjua; Yunin Ludena; Cindy T McEvoy; Rachel L Miller; Noel T Mueller; Thomas G O'Connor; Emily Oken; T Michael O'Shea; Frederica Perera; Joseph B Stanford; Katherine Rivera-Spoljaric; Andrew Rundle; Leonardo Trasande; Rosalind J Wright; Yue Zhang; Yeyi Zhu; Kiros Berhane; Frank Gilliland; Lida Chatzi Journal: Epidemiology Date: 2022-01-01 Impact factor: 4.860
Authors: Rebecca Clarke; Gemma Heath; Prasad Nagakumar; Helen Pattison; Claire Farrow Journal: Int J Environ Res Public Health Date: 2021-03-26 Impact factor: 3.390
Authors: Caseng Zhang; Matt Hicks; Maria B Ospina; Vishnu Martha; Ghiath Alnouri; Liz Dennett; Robert Sataloff; Anne Hicks Journal: Pediatr Pulmonol Date: 2022-04-22
Authors: Bronwyn K Brew; Emma Caffrey Osvald; Tong Gong; Anna M Hedman; Kirsten Holmberg; Henrik Larsson; Jonas F Ludvigsson; Mwenya Mubanga; Awad I Smew; Catarina Almqvist Journal: Clin Exp Allergy Date: 2022-07-28 Impact factor: 5.401